Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Xetra  >  Bayer AG    BAYN   DE000BAY0017


News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Bayer : launches latest fungicide innovation, iblon™ technology

share with twitter share with LinkedIn share with facebook
share via e-mail
09/10/2019 | 03:42am EDT
Tuesday - September 10, 2019
Bayer launches latest fungicide innovation, iblon™ technology
Isoflucypram, member of a newly introduced chemical subclass in the family of Succinate Dehydrogenase Inhibitors (SDHIs), is the core of iblon™ technology / iblon™ technology delivers excellent disease control leading to healthy-looking and consistently higher yielding cereal crops
download'Effective disease management in wheat relies on accurate diagnosis and innovative tools like the iblon™ technology, developed by Bayer.'

Monheim, September 10, 2019 - Bayer announced today that its latest fungicide innovation marketed under the iblon™ technology brand has received first registration worldwide from the New Zealand Ministry for Primary Industries. iblon™ technology is based on the active ingredient isoflucypram, a member of a new subclass in the family of the highly valued SDHIs. It provides excellent disease control resulting in healthy-looking crops that deliver consistently higher yields compared to currently available market standards. The product will be available in New Zealand for the 2019/2020 cereal growing season. Further product launches for iblon™ technology fungicides are expected in other important cereal producing countries once regulatory approval has been completed.

Cereal farmers need innovative and tailored solutions to tackle their daily challenges like limited natural resources, volatile commodity prices and climatic change while feeding a growing world population with high-quality cereals. 'The world cereal market requires higher grain quality and production. In addition to the pressure of climatic hazards such as drought, fungal diseases can cause significant yield losses and quality reductions,' said Hartmut van Lengerich, global Head of Crop Protection Asset Management at Bayer. 'We're excited that our newly-registered iblon™ technology will provide cereal growers in New Zealand with a new and powerful tool to sustainably support increased cereal production'

Isoflucypram has an outstanding and long-lasting efficacy against major economically important fungal diseases: Field trials showed excellent efficacy against major leaf diseases such as leaf blotch, net blotch, yellow rust, and brown rust. The outstanding disease control results in an extended period of green leaf retention, setting the crop up for maximum yield potential.

'Bayer's position as a leading innovator in agriculture has given us the unique opportunity to offer cereal growers in New Zealand the best-in-class SDHI fungicide,' explained Neil Waddingham, Customer Marketing Manager at Bayer New Zealand. 'We are very proud of our new iblon™ technology. Products powered by iblon™ technology have delivered increased yield compared to competitor standards in field trials conducted under New Zealand conditions. In the 2018/19 season the average yield increase in wheat was 0.5 t/ha and in barley 0.25 t/ha. It empowers our customers to be more efficient and sustainable at all levels of their business.'

Isoflucypram offers cereal growers long lasting protection against fungal activity, allowing for a prolonged grain-filling period. It is expected that further products powered by iblon™ technology will be released in the future, providing New Zealand farmers with even further opportunities to optimize their farm production. iblon™ technology delivers all of these benefits at low application rates in wheat, barley, triticale and ryegrass; more information on operator and environmental protection, diseases controlled, and application timing is included in the product label.

iblon™ is a Trademark of the Bayer Group.

About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2018, the Group employed around 117,000 people and had sales of 39.6 billion euros. Capital expenditures amounted to 2.6 billion euros, R&D expenses to 5.2 billion euros. For more information, go to www.bayer.com.

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.


Bayer AG published this content on 10 September 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 September 2019 07:41:01 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BAYER AG
09:38aJ&J'S JANSSEN : FDA OK's Xarelto in Acutely Ill Medical Patients
08:46aBAYER : U.S. FDA approves rivaroxaban to help prevent blood clots in acutely ill..
08:30aJohnson & Johnson's Legal Challenges Mount
06:21aBAYER : Neptra® receives positive CVMP opinion for launch in Europe
10/10BAYER : inks deals with eleven startups under G4A Digital Health Partnerships pr..
10/10Sensyne Widens Bayer Partnership to Include Heart Disease
10/10BAYER : launches LifeHub UK focused on Artificial Intelligence to optimize data-..
10/09BAYER : Ginkgo Bioworks raises $350 million fund for biotech spinouts
10/09BAYER : to Advance Ionis Pharma's Clotting Medicine
10/08BAYER AKTIENGESELLSCHAFT : Release according to Article 40, Section 1 of the WpH..
More news
Financials (EUR)
Sales 2019 46 043 M
EBIT 2019 7 933 M
Net income 2019 3 134 M
Debt 2019 37 328 M
Yield 2019 4,36%
P/E ratio 2019 20,8x
P/E ratio 2020 13,5x
EV / Sales2019 2,13x
EV / Sales2020 2,00x
Capitalization 60 821 M
Duration : Period :
Bayer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 79,26  €
Last Close Price 65,24  €
Spread / Highest target 88,5%
Spread / Average Target 21,5%
Spread / Lowest Target -40,6%
EPS Revisions
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Wolfgang U. Nickl Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
Sector and Competitors
1st jan.Capitalization (M$)
BAYER AG7.69%67 206
JOHNSON & JOHNSON0.01%346 602
ROCHE HOLDING AG18.02%248 022
MERCK AND COMPANY10.38%215 942
PFIZER-17.27%199 726
NOVARTIS14.95%199 287